Could a lighter immunotherapy schedule keep advanced cancers in check?
NCT ID NCT05078047
First seen Jul 17, 2026 · Last updated Jul 17, 2026
Summary
This trial is for people with advanced cancers who have already responded well to 6 months of standard immunotherapy. It compares continuing the same drugs at the usual frequency versus giving them every 3 months. The goal is to see if the reduced schedule can prevent cancer progression just as effectively while lowering side effects and treatment costs.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- immunotherapy drugs (checkpoint inhibitors) given at reduced frequency
- What this could lead to
- If successful, this could mean many patients with advanced cancers need fewer hospital visits for immunotherapy, reducing side effects and costs without compromising disease control.
- What could go wrong
- This is a large phase 3 trial, but reducing treatment frequency might allow some cancers to progress faster. Results will take years to confirm.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BASAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CH Boulogne sur Mer
Boulogne-sur-Mer, France
-
CHD Vendée
La Roche-sur-Yon, France
-
CHI Elbeuf
Saint-Aubin-lès-Elbeuf, France
-
CHU Bordeaux - Hôpial Saint André
Bordeaux, France
-
CHU Bretonneau
Tours, 37044, France
-
CHU Henri Mondor
Créteil, 94010, France
-
CHU Nîmes/Institut de cancérologie du Gard
Nîmes, France
-
CHU Poitiers
Poitiers, 86000, France
-
Centre Antoine Lacassagne
Nice, 06189, France
-
Centre Eugene Marquis
Rennes, 35042, France
-
Centre François Baclesse
Caen, 14076, France
-
Centre Georges François Leclerc
Dijon, 21079, France
-
Centre Gustave Roussy
Villejuif, France
-
Centre Hospitalier Intercommunal
Créteil, 94010, France
-
Centre Hospitalier Mémorial de Saint-Lô
Saint-Lô, France
-
Centre Hospitalier de la Côte Basque
Bayonne, 64109, France
-
Centre Jean Perrin
Clermont-Ferrand, 63000, France
-
Centre Léon Bérard
Lyon, France
-
Centre Oscar Lambret
Lille, France
-
Clinique Chenieux
Limoges, 87000, France
-
Clinique Mutualiste de l'Estuaire
Saint-Nazaire, France
-
Clinique Sainte Catherine
Avignon, 84918, France
-
GH Mutualiste de Grenoble
Grenoble, France
-
HIA Sainte Anne
Toulon, France
-
Hospices Civils de Lyon
Lyon, 69310, France
-
Hôpital Cochin APHP
Paris, France
-
Hôpital Foch
Suresnes, 92151, France
-
Hôpital Saint Antoine APHP
Paris, France
-
Hôpital Saint Louis
Paris, 75010, France
-
ICANS
Strasbourg, 67200, France
-
IUCT
Toulouse, 31059, France
-
Institut de cancérologie de l'Ouest
Angers, 49055, France
-
Institut de cancérologie de l'Ouest
Saint-Herblain, 44805, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can laser or ozone therapy better soothe cancer-related mouth pain? a head-to-head comparison
- Can a cancer vaccine prime the body to better fight liver tumors?
- Open-Face mask may improve comfort and accuracy in head and neck cancer radiation
- Can a radioactive tracer reveal whether immunotherapy is working?
- Training the immune system to hunt down leftover liver cancer cells
- Can a new nucleotide analogue boost cancer treatment?